Strategy
MSTR
Tesla
TSLA
MARA Holdings
MARA
4
Meta Platforms
META
5
Salesforce
CRM
US Stock MarketDetailed Quotes
ACAD ACADIA Pharmaceuticals
- 14.430
- -0.230-1.57%
Close Apr 29 16:00 ET
2.41BMarket Cap10.61P/E (TTM)
14.680High14.380Low1.59MVolume14.660Open14.660Pre Close23.02MTurnover1.39%Turnover Ratio10.61P/E (Static)166.79MShares20.68052wk High3.28P/B1.65BFloat Cap13.40052wk Low--Dividend TTM114.38MShs Float58.720Historical High--Div YieldTTM2.05%Amplitude0.650Historical Low14.501Avg Price1Lot Size
About ACADIA Pharmaceuticals Company
ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
Company Profile
SymbolACAD
Company NameACADIA Pharmaceuticals
Listing DateMay 27, 2004
Issue Price7.00
Founded1993
CEOMs. Catherine Owen Adams
MarketNASDAQ
Employees654
Fiscal Year Ends12-31
Address12830 El Camino Real,Suite 400
CitySan Diego
ProvinceCalifornia
CountryUnited States of America
Zip Code92130-3331
Phone1-858-558-2871
Websitehttp://www.acadia.com
Company Executives
- Name
- Position
- Salary
- Catherine Owen Adams
- Director and Chief Executive Officer
- 7.59M
- James K. Kihara
- Senior Vice President, Finance, Controller and Chief Accounting Officer
- --
- Jennifer J. Rhodes
- Executive Vice President, Chief Legal Officer and Secretary
- 3.27M
- Thomas A. Garner
- Executive Vice President and Chief Commercial Officer
- --
- Mark C. Schneyer
- Executive Vice President and Chief Financial Officer
- 2.52M
- Dr. Elizabeth H.Z. Thompson, PhD
- Executive Vice President and Head of Research and Development
- 4.26M
- Dr. Stephen R. Biggar,M.D.,PhD
- Chairman of the Board
- 386.13K
- James F. Daly
- Independent Director
- --
- Laura A. Brege
- Independent Director
- 403.22K
- Julian C. Baker
- Independent Director
- 341.13K
- James M. Daly
- Independent Director
- 398.22K
- Daniel B. Soland
- Independent Director
- 398.22K
- Dr. Elizabeth A. Garofalo, M.D.
- Independent Director
- 388.22K
- Dr. Edmund P. Harrigan, M.D.
- Independent Director
- 398.22K
- Dr. Adora Ndu, Pharm.D.
- Independent Director
- 408.22K
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀